A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 LymphStat-B是一种全人抗BLyS的IgG1单抗。这项研究是一项II期多中心、双盲、安慰剂对照剂量范围研究，旨在评估淋巴状态B抗体(抗BLyS单抗)在系统性红斑狼疮患者中的安全性、耐受性和有效性，旨在评估淋巴状态B的安全性、耐受性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. LymphoStat-B is a fully human IgG1 monoclonal antibody to BLyS. The study, a phase II multi-center, double-blind, placebo-controlled dose-ranging study to evaluate the safety, tolerability and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus, is designed to evaluate the safety and tolerability and efficacy of LymphoStat-B.